ID   WIL2 H35.1.1
AC   CVCL_A6HU
SY   H35.1.1; WI-L2 AGR 35sc 1.1
DR   Wikidata; Q107117456
RX   PubMed=6286839;
CC   Group: Hybridoma fusion partner cell line.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A6HQ ! WIL2 AGr9 clone 35-1
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 20-05-21; Last updated: 29-06-23; Version: 4
//
RX   PubMed=6286839; DOI=10.1084/jem.156.3.930;
RA   Chiorazzi N., Wasserman R.L., Kunkel H.G.;
RT   "Use of Epstein-Barr virus-transformed B cell lines for the generation
RT   of immunoglobulin-producing human B cell hybridomas.";
RL   J. Exp. Med. 156:930-935(1982).
//